 promoter specificities. We also identified the vulnerabilities of drug candidates to the evolution of drug resistance by using PACE to evolve proteases that are resistant to HCV protease inhibitors currently used in human clinical trials. In addition, we developed important PACE capabilities beyond basic positive selection, including small- molecule modulation of selection stringency and negative
promoter specificities. We also identified the vulnerability of drug campaigner to the evolution of drug resistance by using PACE to develop proteases that are resistant to HCV protease inhibitors presently use in human clinical trials. In accession, we developed important PACE capability beyond basic positive selection, include small- molecule modulation of selection stringency and negative
 prlmoter specificities. We xlso identified the vunnerabjlities uf drug candidates to the evllytion of drug resistance by using PABE to evoove kroteases that arx resistant to MCV pxovease inhibitorx currentlf used in humat zlnnical trials. In addition, we developqd impottwnt PACE capabylitpef begond basic positive selection, inclhding skall- molecule modulation of selection shrinhency and negative
promoter specificities. We also identified the vulnerabilities candidates the evolution drug resistance by that resistant to HCV inhibitors currently used human clinical trials. In addition, we important PACE capabilities beyond basic positive selection, including small- molecule modulation of selection and negative
 promoter specificities. We alSo identifiEd the VulNerAbIlitIes oF drug candidateS To thE evolution of drug resistAnce bY uSIng PacE To evoLve protEAsES ThaT aRe ResIsTAnT to HCv prOtease iNhibitors cUrrEnTly used in humAN cLinical triAls. in addition, we DevEloped ImPorTAnt PAcE cApabiLities BEyond bAsic positIvE SelectIOn, incluDINg SmalL- molecule modulatiON oF Selection strinGency aNd NEgATIve
 promoter specificities. W e also ide ntifi edthe  v ulne rabi lities of drug cand idates to the evolutio n ofdr u g re s is tance  by usi n gP A CEto  e vol ve pr oteas esthat ar e resistan t t oHCV protease in hibitors c urr ently used i n h uman c li nic a l tri als . Inadditi o n, wedeveloped  i m portan t  PACE c a p ab ilit ies beyond basicp os i tive selection , incl ud i ng s mal l-molecule m od ulati o n of se l ec t i o n s t ringency andnegative
 promoter_specificities. We_also identified the vulnerabilities_of drug_candidates_to the_evolution_of drug resistance_by using PACE_to evolve proteases that_are resistant to_HCV_protease inhibitors currently used in human clinical trials. In addition, we developed important PACE_capabilities_beyond basic_positive_selection,_including small- molecule modulation of_selection stringency and negative